alosetron Side Effects
Also known as: Lotronex
Analysis of 73 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
73
Death-Related
8
11.0% of reports
Hospitalizations
18
24.7% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 8 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 6 |
| AMYOTROPHIC LATERAL SCLEROSIS | 1 |
| CARDIAC FAILURE CONGESTIVE | 1 |
| CLOSTRIDIUM DIFFICILE COLITIS | 1 |
| FEELING JITTERY | 1 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 1 |
| INTENTIONAL DRUG MISUSE | 1 |
| OFF LABEL USE | 1 |
| OVERDOSE | 1 |
| PARKINSON^S DISEASE | 1 |
| PLASMA CELL MYELOMA | 1 |
| WEIGHT DECREASED | 1 |
Reactions in Hospitalization Reports
Top reactions in 18 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DIARRHOEA | 6 |
| FAECALOMA | 3 |
| INFECTION | 3 |
| ABDOMINAL PAIN | 2 |
| ANXIETY | 2 |
| CONDITION AGGRAVATED | 2 |
| HIP ARTHROPLASTY | 2 |
| KNEE ARTHROPLASTY | 2 |
| LARGE INTESTINAL OBSTRUCTION | 2 |
| LUNG NEOPLASM MALIGNANT | 2 |
| MUSCLE SPASMS | 2 |
| OFF LABEL USE | 2 |
| PNEUMONIA | 2 |
| POST PROCEDURAL COMPLICATION | 2 |
| VARICOSE VEIN | 2 |
| WEIGHT DECREASED | 2 |
| ABDOMINAL DISTENSION | 1 |
| ANAL INCONTINENCE | 1 |
| APPENDICECTOMY | 1 |
| APPETITE DISORDER | 1 |
Nearby — Related Medications
What the FAERS Data Reveals About alosetron Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 73 voluntary reports linked to alosetron and its brand equivalents (Lotronex), spanning 2004 through 2025. Of those, 8 (11.0%) listed death as an outcome and 18 (24.7%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 83% were female and 17% male; age distribution skews toward 45-64, with 19 reports in that bracket. The single most reported reaction is drug ineffective with 11 submissions, followed by diarrhoea and nausea.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.